Skills this job asks for
TranslationProduct managementLeadershipCRMMachine learningLLMsCompliance
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Glaxosmithkline LLC paid sponsored hires in similar roles3 certified filings for “Principal Scientist, Biologic AI Research and Design” (Medical Scientists, Except Epidemiologists) in MA: $119k–$148k, median $130k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles
- 3 certified filings for “Principal Scientist, Biologic AI Research and Design” (Medical Scientists, Except Epidemiologists) in MA: $119k–$148k, median $130k. Most were filed at wage level I (67%) — 1 lottery entry, ≈15% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Business Introduction
GSK remains committed to achieving bold commercial ambitions for the future. By 2031, we aim to deliver £40 billion in annual sales, leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patients globally. Our Ahead Together strategy is centred on early intervention to prevent and alter the course of disease, thereby protecting people and supporting healthcare systems.
Our diverse portfolio consists of vaccines, specialty medicines, and general medicines.
Through continuous innovation and a dedicated focus on scientific and technical excellence, we strive to develop and launch new, groundbreaking treatments that address critical health challenges.
GSK remains committed to achieving bold commercial ambitions for the future. By 2031, we aim to deliver £40 billion in annual sales, leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patients globally. Our Ahead Together strategy is centered on early intervention to prevent and alter the course of disease, thereby protecting people and supporting healthcare systems.
Our diverse portfolio consists of vaccines, specialty medicines, and general medicines.
Through continuous innovation and a dedicated focus on scientific and technical excellence, we strive to develop and launch new, groundbreaking treatments that address critical health challenges.
This role sits in the US Commercial and Digital Experience Technology team and owns the growth agenda: using generative and predictive AI to accelerate HCP and patient outcomes across the full commercial funnel — awareness, acquisition, conversion, adherence, and loyalty — and translating that into measurable brand growth (NRx/TRx lift, share, HCP reach and frequency, patient persistency). Every capability operates inside a heavily regulated pharma environment: FDA promotional rules, PhRMA Code, and Medical/Legal/Regulatory (MLR) review. You set the AI-for-growth vision, build the models-to-production pipeline in partnership with engineering and data science, and prove commercial impact brand by brand before scaling across the therapeutic portfolio.
This role will provide YOU the opportunity to lead key activities to progress YOUR career. These responsibilities include some of the following:
• Commercial Growth Agenda: Own the AI-driven growth capabilities roadmap across the HCP and patient funnel — awareness, acquisition, conversion, adherence/persistency, and loyalty — reporting impact in brand-relevant commercial terms (NRx/TRx, market share, customer (HCP, Patients) reach/frequency, patient starts rather than generic marketing metrics.
• AI Product Vision for Commercial Growth: Define the multi-year roadmap for applied AI across US Commercial and Digital experience — generative content engines, conversational AI, predictive customer (HCP and patient) models, next-best-action/next-best-offer — anchored to brand growth targets set with Commercial Leadership and Brand teams.
• Growth AI Agents: Build autonomous and semi-autonomous agents that generate, test, and optimize creative, targeting, and channel mix for customer (HCP and patient) support programs in real time, within approved claims and label language.
• Personalization at the Point of Prescribing/Care: Lead AI-driven personalization and dynamic content generation that shortens concept-to-MLR-approved-asset time, that plug into existing content and campaign management, CRM etc. platforms, reducing time from concept to MLR-approved asset.
• Model-to-Production for Commercial Use Cases: Partner with Data Science/ML Engineering to move growth models (LLMs, recommender systems, propensity/NBA models) f
Apply on employer site ↗